Expansion into Clinical Diagnostics Using the Fully Automated geneLEAD Genetic Diagnostic Instrument
First written in FY2016. 22 of 36 entries say "Advanced", first in FY2017-Q1. Latest entry: FY2026.
4 other companies' latest entry also says "Advanced".
- FY2026AdvancedAnnual report
「Clinical diagnostic instruments performed steadily, and sales of nucleic acid extraction reagents, related consumables and maintenance-related products increased alongside higher instrument sales.」
Higher sales of clinical diagnostic instruments also boosted sales of nucleic acid extraction reagents, related consumables and maintenance-related products. - FY2025AdvancedAnnual report
「Clinical diagnostic instruments performed steadily, and sales of nucleic acid extraction reagents, related consumables and maintenance-related products increased alongside higher instrument sales.」
Higher sales of instruments, including clinical diagnostic instruments, generated spillover sales of related reagents, consumables and maintenance products. - FY2025-H1AdvancedAnnual report
「Sales in the six-month period of the current consolidated fiscal year were ¥900 million, up 36.7% year on year, driven by higher sales of OEM instruments.」
Higher OEM instrument sales drove clinical diagnostic instrument sales to ¥900 million, up 36.7% year on year. - FY2024AdvancedAnnual report
「In the current consolidated fiscal year, net sales were ¥1,525 million, up 19.9% year on year.」
Clinical diagnostic instrument sales were ¥1,525 million, up 19.9% year on year, turning to growth after the decline in FY2023. - FY2024-Q3AdvancedAnnual report
「This segment covers sales of instruments for the field of clinical diagnostics using genetic technologies. In the cumulative first three quarters of the current consolidated fiscal year, net sales were ¥1,041 million, up 11.7% year on year.」
Clinical diagnostic instrument sales were ¥1,041 million, up 11.7% year on year, turning to growth after the decline in FY2024-Q2. - FY2024-Q2Continued decline in clinical diagnostic instrument salesAnnual report
「This segment covers sales of instruments for the field of clinical diagnostics using genetic technologies. In the cumulative first two quarters of the current consolidated fiscal year, net sales were ¥659 million, down 12.7% year on year.」
Clinical diagnostic instrument sales were ¥659 million, down 12.7% year on year, declining again after the increase in FY2024-Q1. - FY2024-Q1AdvancedAnnual report
「Our business scope is expanding into the field of clinical diagnostics using genetic technologies. In addition to our traditional R&D activities, we intend to focus on expanding this field. In the cumulative first quarter of the current consolidated fiscal year, net sales were ¥395 million, up 62.6% year on year.」
Clinical diagnostic instrument sales were ¥395 million, up 62.6% year on year, turning to growth from declines in the same period of the previous year and in FY2023 as a whole. - FY2023Continued decline in clinical diagnostic instrument salesAnnual report
「In the current consolidated fiscal year, net sales were ¥1,271 million, down 22.3% year on year.」
Although the policy of expanding the clinical diagnostics field was maintained, clinical diagnostic instrument sales were ¥1,271 million, down 22.3% year on year. - FY2023-Q3Continued decline in clinical diagnostic instrument salesAnnual report
「Our business scope is expanding into the field of clinical diagnostics using genetic technologies. In addition to our traditional R&D activities, we intend to focus on expanding this field. In the cumulative first three quarters of the current consolidated fiscal year, net sales were ¥932 million, down 24.7% year on year.」
Although the policy of expanding the clinical diagnostics field was maintained, clinical diagnostic instrument sales were ¥932 million, down 24.7% year on year. - FY2023-Q2AdvancedAnnual report
「Our business scope is expanding into the field of clinical diagnostics using genetic technologies. In addition to our traditional R&D activities, we intend to focus on expanding this field. In the cumulative first two quarters of the current consolidated fiscal year, net sales were ¥755 million, up 16.1% year on year.」
Clinical diagnostic instrument sales were ¥755 million, up 16.1% year on year, resulting in higher sales than in the same period of the previous year. - FY2023-Q1Continued decline in clinical diagnostic instrument salesAnnual report
「Our business scope is expanding into the field of clinical diagnostics using genetic technologies. In addition to our traditional R&D activities, we intend to focus on expanding this field. In the cumulative first quarter of the current consolidated fiscal year, net sales were ¥243 million, down 17.7% year on year.」
Although the policy of expanding the clinical diagnostics field was maintained, clinical diagnostic instrument sales were ¥243 million, down 17.7% year on year. - FY2022Continued pullback in clinical diagnostic instrument salesAnnual report
「In the current consolidated fiscal year, net sales were ¥1,636 million, down 39.5% year on year. The decline in sales resulted from a pullback following the substantial expansion in sales of fully automated PCR testing instruments for the domestic market and to エリテック in the previous fiscal year.」
Clinical diagnostic instrument sales fell to ¥1,636 million, down 39.5% year on year, due to a pullback following the expansion in sales of fully automated PCR testing instruments for the domestic market and to エリテック in the previous fiscal year. In addition, expansion of test items through the conclusion of a PCR reagent procurement agreement was identified as a strategic business initiative. - FY2022-Q3Continued pullback in clinical diagnostic instrument salesAnnual report
「Our business scope is expanding into the field of clinical diagnostics using genetic technologies. In addition to our traditional R&D activities, we intend to focus on expanding this field. In the cumulative first three quarters of the current consolidated fiscal year, net sales were ¥1,237 million, down 43.5% year on year. The decline in sales resulted from a pullback following the substantial expansion in sales of fully automated PCR testing instruments for the domestic market and to エリテック in the previous fiscal year.」
Clinical diagnostic instrument sales fell to ¥1,237 million, down 43.5% year on year, due to a pullback following the substantial expansion in sales of fully automated PCR testing instruments for the domestic market and to エリテック in the previous fiscal year. - FY2022-Q2Continued pullback in clinical diagnostic instrument salesAnnual report
「Our business scope is expanding into the field of clinical diagnostics using genetic technologies. In addition to our traditional R&D activities, we intend to focus on expanding this field. In the cumulative first two quarters of the current consolidated fiscal year, net sales were ¥650 million, down 56.3% year on year. The decline in sales resulted from a pullback following the substantial expansion in sales of fully automated PCR testing instruments for the domestic market and to エリテック in the previous fiscal year.」
Clinical diagnostic instrument sales fell to ¥650 million, down 56.3% year on year, due to a pullback following the expansion in sales of fully automated PCR testing instruments for the domestic market and to エリテック in the previous fiscal year. - FY2022-Q1Pullback in clinical diagnostic instrument salesAnnual report
「In the cumulative first quarter of the current consolidated fiscal year, net sales were ¥295 million, down 58.0% year on year. The decline in sales resulted from a pullback following the substantial expansion in sales of fully automated PCR testing systems for the domestic market and to エリテック in the previous fiscal year.」
Clinical diagnostic instrument sales fell to ¥295 million, down 58.0% year on year, due to a pullback following the substantial expansion in sales of fully automated PCR testing systems for the domestic market and to エリテック in the previous fiscal year. - FY2021AdvancedAnnual report
「In the current consolidated fiscal year, net sales were ¥2,706 million, up 109.0% year on year. Sales increased substantially year on year, driven by strong sales of fully automated PCR testing instruments for the domestic market and to エリテック.」
Strong sales of fully automated PCR testing instruments for the domestic market and to エリテック drove clinical diagnostic instrument sales up 109.0% year on year to ¥2,706 million. - FY2021-Q3AdvancedAnnual report
「Our business scope is expanding into the field of clinical diagnostics using genetic technologies. In addition to our traditional R&D activities, we intend to focus on expanding this field. In the cumulative first three quarters of the current consolidated fiscal year, net sales were ¥2,191 million, up 145.7% year on year. The increase in sales resulted from strong sales of fully automated PCR testing systems for the domestic market and to エリテック.」
Strong sales of fully automated PCR testing systems for the domestic market and to エリテック drove clinical diagnostic instrument sales to ¥2,191 million, up 145.7% year on year. - FY2021-Q2AdvancedAnnual report
「Our business scope is expanding into the field of clinical diagnostics using genetic technologies. In addition to our traditional R&D activities, we intend to focus on expanding this field. In the cumulative first two quarters of the current consolidated fiscal year, net sales were ¥1,488 million, up 143.8% year on year. The increase in sales resulted from strong sales of fully automated PCR testing systems for the domestic market and to エリテック.」
Strong sales of fully automated PCR testing systems for the domestic market and to エリテック drove clinical diagnostic instrument sales to ¥1,488 million, up 143.8% year on year. - FY2021-Q1AdvancedAnnual report
「Our business scope is expanding into the field of clinical diagnostics using genetic technologies. In addition to our traditional R&D activities, we intend to focus on expanding this field. In the cumulative first quarter of the current consolidated fiscal year, net sales were ¥702 million, up 202.1% year on year. The increase in sales resulted from strong sales of fully automated PCR testing systems for the domestic market and to エリテック.」
Strong sales of fully automated PCR testing systems for the domestic market and to エリテック drove clinical diagnostic instrument sales to ¥702 million, up 202.1% year on year. - FY2020AdvancedAnnual report
「In Japan, fully automated PCR testing instruments and PCR reagents for COVID-19 testing became eligible for coverage under the national health insurance system, and sales began on 3 August of this year. Going forward, we will work diligently to expand the range of PCR reagent test items covered by insurance and to promote the PSS automated system, thereby contributing to society by helping prevent pandemics caused by severe infectious diseases.」
For the clinical diagnostics business, including the geneLEAD series, sales of products eligible for national health insurance coverage in Japan began on 3 August 2020, in addition to deployment in Europe. Expansion of the range of covered test items was also announced. - FY2020-Q3AdvancedAnnual report
「Our business scope is expanding into the field of clinical diagnostics using genetic technologies. In addition to our traditional R&D activities, we intend to focus on expanding this field. In the cumulative first three quarters of the current consolidated fiscal year, net sales were ¥891 million, up 24.1% year on year. The increase in sales resulted from strong sales of fully automated PCR testing systems to エリテック.」
Strong sales of fully automated PCR testing systems to エリテック drove a 24.1% year-on-year increase in clinical diagnostic instrument sales to ¥891 million. - FY2020-Q2AdvancedAnnual report
「Our business scope is expanding into the field of clinical diagnostics using genetic technologies. In addition to our traditional R&D activities, we intend to focus on expanding this field. In the cumulative first two quarters of the current consolidated fiscal year, net sales were ¥610 million, up 30.9% year on year. Sales of fully automated genetic testing systems to エリテック were steady, resulting in higher sales.」
Steady sales of fully automated genetic testing systems to エリテック drove clinical diagnostic instrument sales to ¥610 million, up 30.9% year on year. - FY2020-Q1AdvancedAnnual report
「In the cumulative first quarter of the current consolidated fiscal year, net sales were ¥232 million, up 26.4% year on year. Sales of fully automated genetic testing systems to エリテック were steady, resulting in higher sales.」
Steady sales of fully automated genetic testing systems to エリテック drove a 26.4% year-on-year increase in clinical diagnostic instrument sales to ¥232 million. - FY2019AdvancedAnnual report
「Our business scope is expanding into the field of clinical diagnostics using genetic technologies. In addition to our traditional R&D activities, we intend to focus on expanding this field. In the current consolidated fiscal year, net sales were ¥1,085 million, up 46.2% year on year. Meanwhile, operating expenses were ¥1,177 million, up 43.9%, resulting in an operating loss of ¥91 million, compared with an operating loss of ¥75 million in the previous fiscal year. Sales of fully automated genetic testing systems to エリテック remained strong.」
Strong sales to エリテック drove a 46.2% year-on-year increase in clinical diagnostic instrument sales to ¥1,085 million. Meanwhile, the operating loss widened from ¥75 million to ¥91 million. - FY2019-Q3AdvancedAnnual report
「Our business scope is expanding into the field of clinical diagnostics using genetic technologies. In addition to our traditional R&D activities, we intend to focus on expanding this field. In the cumulative first three quarters of the current consolidated fiscal year, net sales were ¥718 million, up 58.4% year on year. Meanwhile, operating expenses were ¥777 million, up 51.6%, resulting in an operating loss of ¥58 million, compared with an operating loss of ¥59 million in the same period of the previous year. The increase in sales resulted from strong sales of fully automated genetic testing systems to エリテック.」
Strong sales to エリテック drove a 58.4% year-on-year increase in clinical diagnostic instrument sales. The operating loss was ¥58 million, narrowing slightly from ¥59 million in the same period of the previous year. - FY2019-Q2AdvancedAnnual report
「Our business scope is expanding into the field of clinical diagnostics using genetic technologies. In addition to our traditional R&D activities, we intend to focus on expanding this field. In the cumulative first two quarters of the current consolidated fiscal year, net sales were ¥466 million, up 46.6% year on year. Meanwhile, operating expenses were ¥502 million, up 37.8%, resulting in an operating loss of ¥36 million, compared with an operating loss of ¥46 million in the same period of the previous year. The increase in sales and improvement in earnings resulted from strong sales of fully automated genetic testing systems to エリテック.」
Strong sales to エリテック drove a 46.6% year-on-year increase in clinical diagnostic instrument sales, while the operating loss narrowed from ¥46 million to ¥36 million. - FY2019-Q1Increase in clinical diagnostics sales and slight widening of lossAnnual report
「In the cumulative first quarter of the current consolidated fiscal year, net sales were ¥184 million, up 34.6% year on year. Meanwhile, operating expenses were ¥200 million, up 31.6%, resulting in an operating loss of ¥16 million, compared with an operating loss of ¥15 million in the same period of the previous year. Sales of fully automated genetic testing systems to エリテック were strong, resulting in higher sales.」
Strong sales of fully automated genetic testing systems to エリテック drove a 34.6% year-on-year increase in sales, while the operating loss edged up from ¥15 million to ¥16 million. - FY2018Increase in clinical diagnostics sales and widening lossAnnual report
「Our business scope is expanding into the field of clinical diagnostics using genetic technologies. In addition to our traditional R&D activities, we intend to focus on expanding this field. In the current consolidated fiscal year, net sales were ¥742 million, up 8.5% year on year. Meanwhile, operating expenses were ¥817 million, up 10.5%, resulting in an operating loss of ¥75 million, compared with an operating loss of ¥55 million in the previous fiscal year.」
Sales of clinical diagnostic instruments increased, but the operating loss widened due to higher operating expenses. - FY2018-Q3Decline in clinical diagnostics sales and widening lossAnnual report
「In the cumulative first three quarters of the current consolidated fiscal year, net sales were ¥453 million, down 12.6% year on year. Meanwhile, operating expenses were ¥513 million, down 10.4%, resulting in an operating loss of ¥59 million, compared with an operating loss of ¥53 million in the same period of the previous year. Although sales of fully automated genetic testing systems to エリテック were strong, sales to other OEM customers were sluggish, resulting in an overall decline in sales.」
Although sales to エリテック were strong, sales to other OEM customers were sluggish, resulting in a 12.6% year-on-year decline in clinical diagnostic instrument sales and a wider operating loss. - FY2018-Q2Decline in clinical diagnostics sales and widening lossAnnual report
「In the cumulative first two quarters of the current consolidated fiscal year, net sales were ¥318 million, down 15.0% year on year. Meanwhile, operating expenses were ¥364 million, down 12.7%, resulting in an operating loss of ¥46 million, compared with an operating loss of ¥43 million in the same period of the previous year.」
Although sales to エリテック were strong, sales to other OEM customers were weak, resulting in lower sales of clinical diagnostic instruments and a wider operating loss. - FY2018-Q1AdvancedAnnual report
「Our business scope is expanding into the field of clinical diagnostics using genetic technologies. In addition to our traditional R&D activities, we intend to focus on expanding this field. In the cumulative first quarter of the current consolidated fiscal year, net sales were ¥136 million, up 6.1% year on year. Meanwhile, operating expenses were ¥152 million, down 2.3%, resulting in an operating loss of ¥15 million, compared with an operating loss of ¥26 million in the same period of the previous year.」
Sales of clinical diagnostic instruments increased 6.1% year on year, while the operating loss narrowed on strong sales of fully automated genetic testing systems to エリテック and lower operating expenses. - FY2017AdvancedAnnual report
「Sales of the fully automated genetic testing system geneLEAD Ⅻ Plus doubled year on year and progressed steadily through OEM partners. However, the impact of a temporary suspension of product shipments at some OEM partners was substantial, resulting in lower sales year on year.」
Regarding geneLEAD Ⅻ Plus, the full-year results reported concrete progress, with sales through OEM channels doubling year on year. However, constraints from shipment suspensions by some OEM customers have continued. - FY2017-Q3RestatedAnnual report
「Sales of the fully automated genetic testing system geneLEAD Ⅻ Plus, launched in September 2015, progressed steadily through OEM partners and doubled year on year. Meanwhile, the impact of a temporary suspension of product shipments at some major OEM partners was substantial, resulting in lower sales and earnings year on year.」
The document reiterated OEM sales of geneLEAD Ⅻ Plus and the doubling of sales year on year, while the impact of shipment suspensions at major OEM partners continued to result in lower sales and earnings. - FY2017-Q2AdvancedAnnual report
「Sales of the fully automated genetic testing system geneLEAD Ⅻ Plus, launched in September 2015, progressed steadily through OEM partners, with recognized sales doubling from the same period of the previous year.」
Sales expansion of geneLEAD Ⅻ Plus through OEM partners continued, with sales doubling year on year. Meanwhile, some major OEM partners continued to be affected by the suspension of shipments. - FY2017-Q1AdvancedAnnual report
「Sales of the new fully automated genetic testing system geneLEAD Ⅻ Plus expanded steadily through OEM partners, but the impact of a temporary suspension of product shipments at some major OEM partners was substantial, resulting in lower sales and earnings year on year.」
Specific progress in expanding the clinical diagnostics field was reported, with sales of geneLEAD Ⅻ Plus expanding through OEM partners. Meanwhile, some major OEM partners were affected by a suspension of shipments. - FY2016First statedAnnual report
「Our original product, the fully automated genetic testing system geneLEAD, automates the entire process from gene extraction through amplification and measurement. Centered on this product, we plan to expand our business into genetic testing for infectious disease diagnostics, including viruses and bacteria, and into companion diagnostics before drug administration to assess drug efficacy based on an individual's characteristics, including in areas such as anticancer drugs.」
The company plans to expand from a business centered on research and development into the clinical diagnostics field, including infectious disease diagnostics and companion diagnostics before drug administration.